Takeda’s Pharmaceutical Development Division has entered into strategic partnerships with Covance and Quintiles to plan and execute global development programs to support new compounds in all therapeutic areas, except oncology.

Takeda will have access to Covance and Quintiles clinical development capabilities and central lab services, with each partner providing resources to support Takeda’s development pipeline. Takeda plans to use a global program-level sourcing strategy to increase operational efficiency. Through these relationships, Takeda will take on a fully virtual outsourcing model combining the expertise of all parties to help improve productivity and facilitate its global growth.

“Takeda is focused on growing its global drug development footprint, especially in Asia, while at the same time ensuring quality and increasing efficiency of our operations,” said Robert Ahlbrandt, Ph.D., senior vice president, global development operations for Takeda’s Pharmaceutical Development Division. “Our new strategic partnerships with Covance and Quintiles will improve the agility and productivity of our drug development activities, helping us to deliver innovative new medicines to patients globally.” @font-face { font-family: “Times”; }@font-face { font-family: “Cambria”; }@font-face { font-family: “Optima”; }p.MsoNormal, li.MsoNormal, div.MsoNormal { margin: 0in 0in 0.0001pt; font-size: 12pt; font-family: “Times New Roman”; }p { margin: 0in 0in 0.0001pt; font-size: 10pt; font-family: “Times New Roman”; }div.Section1 { page: Section1; }